Alliance between Novozymes and Millipore gives a strong position on the biopharmaceutical market
Novozymes and Millipore launched the first product from their alliance to supply animal-free cell culture supplements for bioprocessing. CellPrimeTM rTransferrin AF is the first animal-free alternative to serum-derived human or bovine transferrin.
CellPrime™ is a range of animal-free cell culture supplements that enable customers to utilize defined, animal-free supplements in their biopharmaceutical production processes. The new rTransferrin AF offers superior benefits over current plasma-derived alternatives, including facilitating effective iron uptake into cells for optimal cell culture and is now commercially available in scalable manufacturing quantities.
“We are pleased with the launch of our first commercial product and with the tremendous progress we have made in the first year of the alliance,” said Caspar Foghsgaard, Senior Manager, Novozymes Biopharma. “Both Novozymes and Millipore share a vision for providing biopharmaceutical manufacturers with a broad range animal-free supplements for industrial cell culture applications. The launch of animal-free transferrin for industrial scale production represents the first step toward that shared vision.”
“The expansion of our animal-free cell culture supplements offering is a critical part of our Bioprocess Division’s long-term strategy,” said Andrew Bulpin, Vice President of Millipore’s Upstream Bioprocessing Business Unit. “By working with an industry leader like Novozymes, we can complement our applications expertise to bring new, innovative products to the market that improve productivity and reduce the risk to our customers.”
Millipore is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. For more information visit www.millipore.com.